Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily LLY Bear 1X Shares

17.84
+0.05610.32%
Volume:1.58K
Turnover:28.29K
Market Cap:2.68M
PE:- -
High:18.00
Open:18.00
Low:17.82
Close:17.78
52wk High:31.30
52wk Low:16.40
Shares:150.00K
Float Shares:150.00K
Volume Ratio:0.29
T/O Rate:1.05%
Dividend:1.01
Dividend Rate:5.67%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly announces long-term data on Omvoh in Crohn’s disease

TIPRANKS
·
43 mins ago

Lilly Says Omvoh Maintains Steroid-Free Remission for Three Years in Crohn’s Disease Patients

Reuters
·
48 mins ago

Eli Lilly - Over 90% Maintained Steroid-Free Control Through Three Years

THOMSON REUTERS
·
49 mins ago

Eli Lilly Pushes Into Opioid Use Disorder With New Brenipatide Phase 2 Trial

TIPRANKS
·
1 hour ago

'She spent over $1,000 a month on weight-loss drugs': My son wrecked his finances after meeting his girlfriend. Who's to blame?

Dow Jones
·
Yesterday

Artiva Biotherapeutics Names Elaine Sorg to Board of Directors

Reuters
·
Yesterday

Berenberg Adjusts Price Target on Eli Lilly to $1,050 From $950, Maintains Hold Rating

MT Newswires Live
·
Yesterday

Three multinationals pay almost half of all Irish corporate tax, watchdog says

Reuters
·
Yesterday

U.S. RESEARCH ROUNDUP-EBay, Huntsman, Palo Alto

Reuters
·
Yesterday

Eli Lilly : Berenberg Raises Target Price to $1050 From $950

THOMSON REUTERS
·
Yesterday

Eli Lilly Stock (LLY) in Focus as Zepbound Found to Help Treat Psoriasis

TIPRANKS
·
Feb 18

Lurpak-maker Arla sees lower dairy prices and boost from protein products

Reuters
·
Feb 18

BRIEF-Lilly's Taltz (Ixekizumab) And Zepbound (Tirzepatide) Used Together Delivered Superior Efficacy In First-Of-Its-Kind Phase 3B Trial

Reuters
·
Feb 18

Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study

Reuters
·
Feb 18

Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Delivered Superior Efficacy in First-of-Its-Kind Phase 3B Trial for Adults With Psoriasis and Obesity or Overweight

THOMSON REUTERS
·
Feb 18

Eli Lilly: Taltz, Zepbound Met Primary Endpoint of Superiority VS. Taltz Monotherapy in Achieving Complete Skin Clearance, ≥10% Weight Loss

THOMSON REUTERS
·
Feb 18

Eli Lilly: at 36 Weeks, Treatment With Taltz, Zepbound Met Primary and All Key Secondary Endpoints

THOMSON REUTERS
·
Feb 18

Eli Lilly: in Secondary Endpoint, Patients Taking Taltz, Zepbound Were 40% More Likely to Achieve Pasi 100 Compared to Those Taking Taltz Alone

THOMSON REUTERS
·
Feb 18

'His credit rating is wrecked': My son and his girlfriend mingled their finances. Big mistake.

Dow Jones
·
Feb 18

Daiwa Securities Adjusts Price Target on Eli Lilly to $1,250 From $1,230, Maintains Buy Rating

MT Newswires Live
·
Feb 18